New York State Common Retirement Fund Reduces Stock Position in argenx SE (NASDAQ:ARGX)

New York State Common Retirement Fund lowered its position in shares of argenx SE (NASDAQ:ARGX) by 39.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 63,534 shares of the company’s stock after selling 41,000 shares during the period. New York State Common Retirement Fund owned about 0.11% of argenx worth $39,073,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ARGX. Venturi Wealth Management LLC bought a new position in argenx in the 4th quarter worth $66,000. Nkcfo LLC bought a new position in argenx in the 4th quarter worth $68,000. Advisors Preferred LLC bought a new position in argenx in the 4th quarter worth $73,000. Cromwell Holdings LLC raised its holdings in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in argenx by 44.8% in the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock worth $155,000 after purchasing an additional 78 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the subject of several research reports. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. JMP Securities upped their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 14th. Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and increased their price target for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Piper Sandler increased their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “hold” rating to a “sell” rating in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

argenx Trading Up 1.1 %

Shares of NASDAQ ARGX opened at $647.49 on Friday. The firm has a 50 day moving average of $642.31 and a 200 day moving average of $585.45. The firm has a market capitalization of $39.34 billion, a price-to-earnings ratio of -735.78 and a beta of 0.58. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.